Cancer Therapy & Oncology International Journal最新文献

An Efficient Breast Cancer Detection Using Jelly Electrophorus Optimization Based Deep 3D Convolution Neural Networks (CNN) 基于深度3D卷积神经网络(CNN)的Jelly Electrophorus优化高效乳腺癌检测

Cancer Therapy & Oncology International Journal Pub Date : 2023-09-22 DOI: 10.19080/ctoij.2023.25.556156

Sagar kumar Patel

引用次数: 0

Stomach Cancer – Prevention with a Plant-Based Diet 以植物性饮食预防胃癌

Cancer Therapy & Oncology International Journal Pub Date : 2021-07-27 DOI: 10.19080/ctoij.2021.19.556012

A. Strombom

引用次数: 0

Rare Case of Synchronous Malignancy in Oral Cavity and Esophagus- Case Report 口腔及食道同时恶性肿瘤1例报告

Cancer Therapy & Oncology International Journal Pub Date : 2021-07-23 DOI: 10.19080/ctoij.2021.19.556011

P. Kalra

引用次数: 0

AST/ALT (De ritis) Ratio As a Prognostic Factor in Diffuse Large B-Cell Lymphoma AST/ALT (De - ritis)比值与弥漫性大b细胞淋巴瘤预后的关系

Cancer Therapy & Oncology International Journal Pub Date : 2021-07-19 DOI: 10.19080/ctoij.2021.19.556010

S. Solmaz

{"title":"AST/ALT (De ritis) Ratio As a Prognostic Factor in Diffuse Large B-Cell Lymphoma","authors":"S. Solmaz","doi":"10.19080/ctoij.2021.19.556010","DOIUrl":"https://doi.org/10.19080/ctoij.2021.19.556010","url":null,"abstract":"Purpose: This study aims to evaluate the prognostic significance of the aspartate aminotransferase (AST) / alanine aminotransferase (ALT) (De Ritis) ratio in diffuse large b-cell lymphoma ( DLBCL). Material and Method: This retrospective study analyzed newly diagnosed DLBCL patients between December 2003- November 2016 in our hospital. We used the university archive to analyze patient information. De Ritis ratio were calculated using data from the blood samples at the time of diagnosis. We analyzed the effect of the De Ritis ratio on the overall survival (OS) of 225 patients with DLBCL. Results: The mean age of the patients was 60.3(18–95) years, and 57.7 % of them were males. We performed ROC curve analysis to calculate optimal cut off points for the De Ritis ratio at the time of diagnosed. The median De Ritis ratio was 1.30( range 0,26 - 5,84 ). Based on the cutoff points for the De Ritis ratio, patients were separated in two groups: high De Ritis ratio group ( ≥1.30, n: 101 ) and low De Ritis ratio group ( <1.30, n:154 ) ( with sensitivity of 59%, specifity of 40%). We found a significant relationship between OS and De Ritis ratio. In Kaplan Meier analyses, the group with a higher De Ritis ratio had a more unfavorable prognosis for OS ( p=0.027). Conclusion: The De Ritis ratio may provide a cost- effective and sustainable marker for DLBCL patients. A higher De Ritis ratio can be considered as an independent prognostic factor in DLBCL patients.","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"78 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90797795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Skeletal Muscle Metastases in Carcinoma Hypo Pharynx – a Rare Occurrence 咽下癌骨骼肌转移-罕见的发生

Cancer Therapy & Oncology International Journal Pub Date : 2021-07-09 DOI: 10.19080/ctoij.2021.19.556008

Swati Virmani

引用次数: 0

The Luxated Eddies-Ectopic Meningioma 脱位涡流-异位脑膜瘤

Cancer Therapy & Oncology International Journal Pub Date : 2021-06-24 DOI: 10.19080/ctoij.2021.19.556007

Anu Bajaj

引用次数: 0

Multiple Myeloma Presenting as a Left Clavicular Swelling – A Case Report 多发性骨髓瘤表现为左锁骨肿胀1例报告

Cancer Therapy & Oncology International Journal Pub Date : 2021-06-22 DOI: 10.19080/ctoij.2021.19.556005

Dilbag Singh

引用次数: 0

Chemotherapy Induced Peripheral Neuropathy in Breast Cancer Patients 化疗诱导乳腺癌患者周围神经病变

Cancer Therapy & Oncology International Journal Pub Date : 2021-06-22 DOI: 10.19080/ctoij.2021.19.556006

Amani Saleh Hadi Saeed

{"title":"Chemotherapy Induced Peripheral Neuropathy in Breast Cancer Patients","authors":"Amani Saleh Hadi Saeed","doi":"10.19080/ctoij.2021.19.556006","DOIUrl":"https://doi.org/10.19080/ctoij.2021.19.556006","url":null,"abstract":"Peripheral neuropathy induced by chemotherapy is considered the most common neurological disorder associated with chemotherapy. Different sites are involved in the mechanism of chemotherapy induced peripheral neuropathy and considered multifactorial. 68% of cases develop CIPN during the first month following the start of chemotherapy, 60% of cases develop CIPN within 3 months after chemotherapy and only 30% after 6 months. CIPN is caused by chemotherapeutic agents which include taxanes, platinum analogs, and vinca alkaloids. The clinical presentation of CIPN includes multiple symptoms that may cause functioning impairment and may require reduction of the dose of chemotherapy. CIPN considered a common sequel of different agents of chemotherapy and may last from months to years after chemotherapy completion. CIPN can be diagnosed by a detailed history and clinical examination. Clinical examination of a patient with CIPN can be done by the use of nerve conduction studies. Antidepressant includes tricyclic antidepressants and serotonin-noradrenaline reuptake inhibitors are common drugs used for CIPN. Patients may require reductions, substitutions, or stopping of chemotherapeutic agents according to the severity of symptoms.","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"127 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91356965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

FDG-PET Metabolic Vs CT Anatomical Monitoring of Tumor Response to Anterior Chemotherapy in Breast Carcinoma-The Uncertainties FDG-PET代谢与CT解剖监测乳腺癌前路化疗肿瘤反应的不确定性

Cancer Therapy & Oncology International Journal Pub Date : 2021-06-21 DOI: 10.19080/ctoij.2019.18.556003

G. Lohith

{"title":"FDG-PET Metabolic Vs CT Anatomical Monitoring of Tumor Response to Anterior Chemotherapy in Breast Carcinoma-The Uncertainties","authors":"G. Lohith","doi":"10.19080/ctoij.2019.18.556003","DOIUrl":"https://doi.org/10.19080/ctoij.2019.18.556003","url":null,"abstract":"To compare the metabolic tumor response and volumetric tumor response to pathological tumor response to NACT and to predict the sensitivity, specificity, positive predictive value and negative predictive value of FDG PET to neoadjuvant chemotherapy. Material and method: The study was performed after institutional ethical committee clearance.35 consecutive eligible patients treated between January 2015 to May 2016 were included in the study. PETCT was acquired at baseline and post neoadjuvant chemotherapy, prior to surgery. The SUV max of tumor and involved nodes at baseline and post neoadjuvant chemotherapy was compared to pathological tumor size and nodal status. Response was assessed using PRECIST and RECIST criteria. Statistical methods used for analysis were software SPSS version 13, calculations for Sensitivity, specificity, positive predictive value and negative predictive value. Results: The median age was 51.3 years (range 33 to 68 years). The patients were generally healthy with ECOG PS 0-1. FDG PET tumor to HPE correlation -sensitivity, specificity, PPV, NPV SENSITIVITY 88.8% SPECIFICITY 50% PPV 85.7% NPV 57.1% our results show the high sensitivity and low specificity of PETCT in detecting residual tumor. Overall PCR was in 22.6% (8/35). Pathological Complete Response Rates In The Axillary Node Luminal wise:Total:23/35 – 65.7%. Luminal A PCR Rate -14.4%; Luminal B PCR Rate-8.5%; TNBC PCR Rate-31.4%; HER 2-11.4%. Conclusion:","PeriodicalId":9575,"journal":{"name":"Cancer Therapy & Oncology International Journal","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90047364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Loss of EGFR Mutation Expression Induced by NF1 Mutation in Non-Small Cell Lung Cancer: Non-Canonical Pathway of Tyrosine Kinase Inhibitors’ Resistance 非小细胞肺癌中NF1突变诱导的EGFR突变表达缺失:酪氨酸激酶抑制剂耐药的非典型途径

Cancer Therapy & Oncology International Journal Pub Date : 2021-02-16 DOI: 10.19080/ctoij.2021.18.555979

Jose Gabriel Negron Rodriguez, Luis Orrego Poma, Manuel Leiva Gálvez, Maria Claudia Rodriguez Zavaleta, Wuilbert Rodriguez Pantigoso

引用次数: 0